Pfizer presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults, demonstrating that Prevenar 13 prevented a first episode of vaccine-type community-acquired pneumonia in adults 65 years of age and older, the study’s primary objective. This trial is the first in adults to clearly demonstrate a significant reduction in vaccine-type pneumococcal CAP, and importantly, non-bacteremic/non-invasive vaccine-type pneumococcal CAP.